Also trades as: GLAND.BO (BSE) · $vol 6M
GLAND.NS NSE
Gland Pharma Limited
1W: -0.8%
1M: -0.0%
3M: +16.7%
YTD: +52.5%
1Y: +45.5%
3Y: +86.6%
5Y: -25.8%
₹2,896.70 ($30.08)
+22.30 (+0.78%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$12.3B
+34.6% ▲
5Y CAGR: +15.3%
Capital Expenditures
$4.9B
-27.6% ▼
5Y CAGR: +16.5%
Free Cash Flow
$7.4B
+39.7% ▲
5Y CAGR: +14.5%
Dividends Paid
$3.0B
+10.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$8.0B
-63.5% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $16.2B | $10.5B | $7.7B | $7.0B | $10.3B |
| Depreciation & Amort. | $1.1B | $1.5B | $3.4B | $3.8B | $4.2B |
| Stock-Based Comp. | $46M | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$3.9B | -$4.2B | -$532M | -$61M | -$2.5B |
| Other Non-Cash Items | -$1.4B | -$4.2B | -$670M | -$1.6B | $348M |
| Operating Cash Flow | $7.9B | $3.6B | $10.0B | $9.1B | $12.3B |
| — Investing Activities — | |||||
| Capital Expenditures | -$5.2B | -$2.2B | -$3.9B | -$3.8B | -$4.9B |
| Acquisitions (Net) | $6.1B | -$12.7B | -$10.2B | $3M | $6M |
| Investment Purchases | -$16.8B | -$4.7B | -$7.4B | -$5.0B | -$7.4B |
| Investment Sales | $10.7B | $17.4B | $2.7B | $24.4B | $11.4B |
| Other Investing | -$4.8B | $14.3B | $1.3B | $1.5B | $0 |
| Investing Cash Flow | -$10.0B | $12.1B | -$17.6B | $17.0B | -$945M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$1M | -$1M | -$7.6B | -$759M | -$712M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | -$3.3B | -$3.0B |
| Other Financing | -$35M | -$65M | -$437M | -$306M | -$168M |
| Financing Cash Flow | $349M | $149M | -$8.0B | -$4.3B | -$3.8B |
| Net Change in Cash | -$1.7B | $15.9B | -$15.5B | $22.0B | $8.0B |
| Cash End of Period | $3.2B | $19.1B | $3.6B | $25.6B | $33.6B |
| Free Cash Flow | $2.7B | $1.4B | $6.1B | $5.3B | $7.4B |